Retatrutide (20mg)

Retatrutide (LY-3437943) 20mg is the double-dose research vial of Viking Labs' triple-agonist peptide, designed for extended or higher-volume laboratory research protocols. This vial contains twice the peptide quantity of the standard 10mg format, providing cost-effective material for longer-duration studies.

Retatrutide simultaneously engages three G-protein-coupled receptors central to metabolic research: GLP-1R, GIPR, and the glucagon receptor. This tri-agonist profile has been investigated in clinical-stage studies examining multi-receptor metabolic pharmacology. Phase 2 clinical trial publications have documented the compound's activity profile across all three receptor targets. Research has examined the interplay between GLP-1-mediated appetite signaling, GIP-mediated incretin effects, and glucagon-mediated hepatic energy metabolism and thermogenesis.

The 20mg format is particularly suited for research protocols requiring multiple administrations in animal models, dose-response characterization studies, or laboratories conducting parallel experimental arms that demand larger peptide quantities from a single verified batch.

Viking Labs synthesizes this research-grade retatrutide at a USA-based cGMP facility. Each 20mg vial undergoes the same stringent quality controls as the standard format: independent HPLC verification at 99%+ purity, full Certificate of Analysis, batch serialization, and sterile fill under aseptic conditions.

Storage: Store lyophilized peptide at -20C. Once reconstituted, store at 2-8C and use within 28 days. Partial reconstitution is acceptable for multi-use protocols.

For laboratory research use only. Not for human consumption.